Skip to main content
Equibles
TXMD logo

TXMD · TherapeuticsMD, Inc. · Documents

Track TXMD — free

Use TXMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TXMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.75 -0.07 (-3.85%) Q2 2022 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”
View the 10-Q filed Aug 11, 2026
Customer concentration — top 3 customers 100% of revenue

3 customers — 100% of revenue (the three and six months ended June 30, 2026)

“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
View the 10-Q filed Aug 11, 2026
Market Cap
$21.07M
Shares
11.57M
Volume · Nov 5 3554 Avg daily vol (3M) 23.41K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $3.02M up 71.6% 10-K filed Mar 30, 2026 Quarterly report FY2026 Q2 Revenue $869K down 8.7% 10-Q filed Aug 11, 2026 Latest results Financial results 8-K filed Aug 11, 2026 Earnings call Q2 2022 earnings call Held Aug 15, 2022
2026
Aug 11
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $869K ▼ 8.7% Net income $155K ▼ 71.9% Diluted EPS $0.01 ▼ 80.0%
May 12
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $724K ▲ 84.2% Net income $95K Diluted EPS $0.01
Apr 1
Annual report 10-K/A FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $3.02M ▲ 71.6% Net loss $569K Diluted EPS -$0.05
Mar 30
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $3.02M ▲ 71.6% Net loss $569K Diluted EPS -$0.05
2025
Mar 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $1.76M ▲ 35.3% Net loss $2.18M Diluted EPS -$0.19
2024
Mar 29
Annual report 10-K FY2023, ended Dec 31
Annual report for FY2023
Revenue $1.3M ▼ 98.1% Net loss $10.28M Diluted EPS -$0.98
2023
Showing 1–50 of 169 documents
Key facts CIK 25743 CUSIP 88338N206 13F (30d) 10 filings 10 filers Visit website Investor relations